Fig. 7: Long-term clinical efficacy of CD19 CAR T cell products correlates with product BACH2 activity.
From: BACH2 regulates T cell lineage state to enhance CAR T cell function
a, Uniform manifold approximation and projection (UMAP) of CAR T cells from 12 CD19-targeted, 41BB-based, CAR T cell products, labeled by clinical response. b, BACH2 regulon score in CD4 and CD8 TCM cells and TEM cells from manufactured CAR T cell products. The analysis was by two-way ANOVA. c,d, BACH2 regulon score in bulk (c) and CD4 central memory (d) from patients who had an initial response and then either relapsed (n = 3) or remained in remission (n = 6). Boxes represent minima and maxima with the line at mean using significance testing with Student’s t-test. e, Analysis of CD4 TCM cells from patients who relapsed and those who did not. f, Relapse-free survival in patients receiving products with either high or low BACH2 regulon scores. The analysis was by log(rank test). CR, complete remission; NR, no response.
